SIGLEC10 and B-cell chronic lymphocytic leukemia: The findings of the Siglec‐G overexpressing mice suggest that targeting of Siglec‐G/ Siglec‐10 with agents that increase the inhibitory function of this receptor may be a novel treatment option for CLL.